What is The Concinnity?
The Concinnity Company specializes in clinical trial oversight software, with its flagship Cloud Concinnity® platform designed to support Data Safety Monitoring Boards (DSMB) and Data Monitoring Committees. This sophisticated solution centralizes critical data collection, analysis, and reporting functions, thereby enhancing collaboration among stakeholders and ensuring robust compliance throughout the clinical trial lifecycle. The platform is engineered to serve a diverse clientele within the clinical trial ecosystem, aiming to streamline complex processes and elevate decision-making efficiency. By prioritizing patient safety, cost-effectiveness, and accelerating the time-to-market for novel treatments, The Concinnity addresses the dynamic challenges inherent in modern clinical research.
How much funding has The Concinnity raised?
The Concinnity has raised a total of $329K across 2 funding rounds:
Debt
$150K
Debt
$179K
Debt (2020): $150K with participation from PPP
Debt (2021): $179K led by PPP
Key Investors in The Concinnity
PPP
Public-Private Partnership
PPP
Public-Private Partnership
Undisclosed investor
Undisclosed investor participating in the funding round. This entity has contributed capital to support the company's growth initiatives.
What's next for The Concinnity?
With the recent influx of capital and its designation as a large-scale late-stage funding event, The Concinnity is strategically positioned for significant expansion. This investment will likely fuel further development of its Cloud Concinnity® platform, potentially incorporating advanced analytics or AI-driven insights for enhanced trial monitoring. Expansion into new geographic markets or deeper penetration within existing ones is also a probable strategic objective. Furthermore, the company may pursue strategic partnerships or acquisitions to broaden its service offerings or solidify its market leadership in clinical trial oversight technology. The focus remains on leveraging technology to improve patient safety and expedite the delivery of new therapies.
See full The Concinnity company page
